Patricia Piers, PhD, discusses a career of innovation in ophthalmology, looks to future
December 2nd 2022In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.
Read More
Belite Bio finalizes phase 3 clinical trial plans for advanced dry AMD treatment with LBS-008
November 18th 2022LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.
Read More
NeoLight launches ROP risk management software ROPCheck.com for pediatric ophthalmology space
November 17th 2022According to the company, ROP Check builds upon its pediatric retina screening portfolio, adding digital management (schedule, document, bill, and transfer) for treating patients with retinopathy of prematurity.
Read More
Boarding Orbis Flying Eye Hospital: Not your typical flight experience
November 16th 2022When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.
Read More
AEYE Health gains FDA clearance to screen diabetics to head off blindness
November 15th 2022The screening of diabetics for retinopathy has recently become reimbursable in the US, the company noted in its news release, and the approval comes after positive Phase 3 clinical trial earlier this year.
Read More
AI-empowered diagnostic retina scans can help prevent heart and kidney diseases
November 10th 2022Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.
Read More
Harrow rolls out ordering portal for atropine formulations
November 10th 2022According to the company, compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. The prescriptions will be dispensed through Harrow’s wholly owned subsidiary, ImprimisRx.
Read More